Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL

Chiara Buono,* Yifu Li,* Stephen W. Waldo,*† and Howard S. Kruth1,*

Section of Experimental Atherosclerosis,* National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1422 Howard Hughes Medical Institute,† National Institutes of Health Medical Research Scholar Program, Bethesda, MD 20892-1422

Abstract Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Several studies have recently shown that LXRs promote reverse cholesterol transport and inhibit atherosclerosis. Our study investigated whether LXRs affect macrophage uptake of LDL by human monocyte-derived macrophages. We have previously shown that human monocytes differentiated into macrophages with macrophage-colony-stimulating factor (M-CSF) constitutively take up large amounts of native LDL by receptor-independent, fluid-phase pinocytosis. In the research reported here, human monocytes were differentiated to macrophages in the presence of M-CSF with or without the LXR agonists T0901317 or 22(R)-hydroxycholesterol. Then, macrophages were incubated with native 125I-LDL to determine LDL uptake. T0901317 and 22(R)-hydroxycholesterol inhibited 125I-LDL uptake by 68 ± 1% and 69 ± 2%, respectively, and decreased pinocytotic vacuoles in the macrophages. 125I-BSA uptake, a measure of fluid-phase pinocytosis, and 125I-LDL uptake were the same, and T0901317 treatment inhibited uptake of both to the same degree. T0901317 did not affect receptor-mediated uptake of acetylated LDL, showing that the LXR effect is specific for fluid-phase pinocytosis of lipoproteins.

Our results show that LXRs downregulate macrophage pinocytosis of LDL. The findings reveal an additional new mechanism by which LXRs may inhibit macrophage cholesterol accumulation and atherosclerosis, namely, by inhibiting macrophage uptake of LDL.—Buono, C., Y. Li, S. W. Waldo, and H. S. Kruth. Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL. J. Lipid Res. 2007. 48: 2411–2418.

Supplementary key words atherosclerosis • cholesterol • endocytosis

Macrophage uptake of lipoproteins, especially LDL, is considered a critical process in the development of atherosclerosis, causing transformation of the macrophages into foam cells, thus promoting cholesterol accumulation and inflammation in the atherosclerotic plaque (1, 2). Heretofore, researchers believed that macrophages could internalize only modified lipoproteins, typically through a variety of scavenger receptors (3, 4). In recent studies, we have demonstrated an alternative mechanism for macrophage foam cell formation that does not depend on LDL modification or macrophage receptors (5–7). In this mechanism of foam cell formation, macrophages take up LDL through receptor-independent, fluid-phase pinocytosis. Receptor-independent fluid-phase uptake of 125I-LDL does not show saturation of uptake with increasing 125I-LDL concentrations and cannot be inhibited by excess amounts of unlabeled LDL (5, 7). Pinocytosis of fluid and solute such as LDL contained in the fluid can occur either through uptake of fluid by micropinocytosis within small vesicles (micropinosomes) less than 0.1 μm in diameter, or by macropinocytosis within large vacuoles (macropinosomes) usually greater than 1 μm (8, 9). Macropinosomes form from extended plasma membrane folds that fuse back with the plasma membrane, trapping extracellular fluid with the intracellular vacuoles that are formed.

Macrophage pinocytosis of LDL is either constitutive or activated through a protein kinase C-dependent signaling pathway, depending on the macrophage differentiation phenotype. Differentiation of human monocytes in the presence of FBS and macrophage-colony-stimulating factor (M-CSF) produces an elongated macrophage phenotype that shows uptake of large amounts of LDL and accumulation of high levels of cholesterol by constitutive pinocytosis (7). This is the macrophage foam cell model we have studied in this report. Alternatively, human monocytes can be differentiated with human serum or FBS and granulocyte/macrophage-CSF, producing a rounded “fried egg” macro-

Abbreviations: DPBS, Dulbecco’s phosphate-buffered saline; LXR, liver X receptor; M-CSF, macrophage-colony-stimulating factor; PPAR, peroxisome proliferator-activated receptor.

*To whom correspondence should be addressed.
e-mail: kruthh@nhlbi.nih.gov

This article is available online at http://www.jlr.org
phage phenotype that shows LDL uptake and cholesterol accumulation following stimulation of pinocytosis by protein kinase C activation (5, 6, 10). The pinocytosis of fluid that occurs with both macrophage phenotypes is accompanied by vigorous macropinocytosis, suggesting that this mechanism of fluid uptake contributes to the total pinocytic fluid uptake observed in these macrophages.

Several studies have indicated that liver X receptors (LXRs) are important transcription factors involved in the control of lipid metabolism and inflammation (as reviewed in Ref. 11). It has been shown that LXRs inhibit atherosclerosis in experimental mouse studies. Treatment of atherosclerosis-prone LDL receptor- and apolipoprotein E (apoE)-deficient mice with synthetic LXR agonists reduces the development of atherosclerosis (12, 13). Other studies, using macrophage-selective LXR-deficient mice created by bone marrow transplantation, have further established that this reduction in atherosclerosis is dependent on LXR activity in macrophages (14, 15). One possible mechanism by which LXRs inhibit atherosclerosis is by promoting macrophage cholesterol efflux via induction of the genes encoding apoE and ATP binding cassette transporters A1 and G1 in macrophages (16–25). Our study has shown another possible mechanism by which LXRs could also affect atherosclerosis, by decreasing macrophage receptor-independent, fluid-phase pinocytosis of LDL.

**MATERIALS AND METHODS**

**Culture of human monocyte-derived macrophages**

Human monocytes were purified with counterflow centrifugal elutriation of mononuclear cells obtained by monocytepheresis of normal human donors. M-CSF monocyte-derived-macrophage cultures were begun with the elutriated human monocytes suspended in RPMI 1640 medium (MediaTech) with 10% FBS (GIBCO) seeded in 6-well plates (Corning CellBIND) at a density of 2 x 10^5 monocytes/cm^2. After 2 h incubation in a cell culture incubator with 5% CO_2/95% air at 37°C, the monocyte cultures were rinsed three times with RPMI 1640 medium. Then, the monocytes were differentiated into macrophages by culturing with RPMI 1640 medium containing 10% FBS, 100 ng/ml M-CSF (PeproTech), and 25 ng/ml IL-10 (PeproTech) (26) with or without the synthetic LXR agonist T0901317 (5 μM) (Cayman Chemical) or the natural LXR agonist 22(R)-hydroxycholesterol (5 μM) (Sigma-Aldrich). In one experiment, peroxisome proliferator-activated receptor (PPAR) agonists clofibrate (100 nM) (Calbiochem), L165,041 (5 μM) (Sigma-Aldrich), or ciglitazone (5 μM) (Cayman Chemical) were added to the macrophage differentiation medium. The medium was replaced with fresh medium after 6 days of culture, and monocyte-derived macrophages were used for experiments the following day.

For experiments, monocyte-derived macrophage cultures (about 0.2 mg protein/well) were first rinsed three times with serum-free RPMI 1640 medium. Cultures were incubated in serum-free RPMI 1640 medium with the indicated concentration of LDL and the reagents specified in each experiment. Experimental incubations with these monocyte-derived macrophages were carried out in the presence of the same concentration of cytokines and agonists used during differentiation of monocytes into macrophages, unless noted otherwise.

**Preparation of lipoproteins for use in experiments**

Before use, human LDL (Intracel) was dialyzed against 1 l of 0.15 M sodium chloride and 0.3 mM EDTA (pH 7.4) for 12 h at 4°C, then against RPMI 1640 medium (two changes, 1 l each change) for 24 h. Human 125I-LDL and 125I-acetylated LDL (BioMedical Technologies) were dialyzed against 0.15 M sodium chloride and 0.3 mM EDTA (pH 7.4) over 36 h at 4°C (three changes, 1 l each change). All dialysis was carried out with Pierce Slide-A-Lyzer cassettes (10,000 molecular weight cutoff). After dialysis, lipoproteins were sterilized by passage through a 0.45 μm (pore size) low-protein binding filter (Gelman Acrodisc). 125I-LDL specific activity was adjusted to 2.25 x 10^−5 μCi/ng by adding unlabeled LDL dialyzed similar to the 125I-LDL. 125I-acetylated LDL was used at the original specific activity of 37.7 x 10^−5 μCi/ng, as provided by the manufacturer. Lipoprotein concentrations are expressed in terms of protein.

**Assay of 125I-LDL and 125I-acetylated LDL cell association and degradation**

Macrophage cell association and degradation of 125I-LDL and 125I-acetylated LDL were determined according to the methods of Goldstein and Brown (27). Lipoprotein degradation was quantified by measurement of trichloroacetic acid-soluble organic iodide radioactivity in supernatants of culture media samples that were centrifuged at 15,000 g for 10 min. Values obtained in the absence of cells were <5% of those values obtained with cells.

Cell-associated 125I-LDL and 125I-acetylated LDL were determined by rinsing macrophages three times with Dulbecco’s phosphate-buffered saline (DPBS) plus Ca^2+ and Mg^2+, and 0.2% BSA, followed by three times with DPBS plus Ca^2+ and Mg^2+, all at 4°C. Then, macrophages were dissolved overnight in 0.1 N NaOH at 37°C. Aliquots of cell samples were assayed for protein content and 125I radioactivity with a γ counter (28).

**Determination of fluid-phase pinocytosis**

125I-BSA (MP Biomedicals) cell association and degradation by macrophages was determined similar to 125I-LDL described above and served as a means to determine fluid-phase uptake by the macrophages (7, 27). Before incubations, 125I-BSA-specific activity was adjusted to 2.25 x 10^−5 μCi/ng by adding unlabeled BSA. Macrophages were incubated with 250 μg/ml 125I-BSA.

**Depletion of macrophage cholesterol with methyl-β-cyclodextrin**

Macrophage cholesterol content was decreased by treating macrophages with methyl-β-cyclodextrin (Sigma-Aldrich) as previously described (29). Monocytes were cultured for 7 days in differentiation medium with M-CSF and then used for two parallel experiments to determine the effect of methyl-β-cyclodextrin treatment on macrophage cholesterol content and fluid-phase pinocytosis. Macrophages were first incubated for 1 h without or with methyl-β-cyclodextrin (5 mM) in RPMI 1640 without serum. Then, the macrophages were incubated for 5 h in fresh media without or with methyl-β-cyclodextrin and either unlabeled BSA (250 μg/ml) for determination of cholesterol content as previously described (30) or with 125I-BSA (250 μg/ml) for assessment of fluid-phase pinocytosis.

**Statistical analysis**

All data are presented as the mean ± standard error of the mean. The means were determined from three culture wells for each data point. Statistical comparisons of means were made using Student’s t statistic (unpaired). A P value ≤0.05 was considered significant.
RESULTS

LXR agonist decreases macrophage macropinosomes

In a previous study (7), we found that M-CSF-differentiated macrophages contain macropinosome vacuoles that function in constitutive pinocytosis. The constitutive pinocytosis mediates fluid-phase uptake of LDL, causing high levels of macrophage cholesterol accumulation and foam cell formation. In the current study, we observed a noticeable reduction of macropinosome vacuoles in the macrophages when macrophages were differentiated with either T0901317 (Fig. 1), or the natural LXR agonist 22(R)-hydroxycholesterol (not shown). The LXR agonist effect of decreasing macrophage vacuoles suggested a potential inhibitory effect of LXR agonists on macrophage pinocytosis of fluid and consequently, receptor-independent fluid-phase uptake of LDL.

LXR agonist decreases macrophage uptake of LDL

To learn whether LXR agonist treatment affected macrophage uptake of LDL, monocytes were differentiated to macrophages in the presence of T0901317 or 22(R)-hydroxycholesterol for 7 days and were then incubated for 1 day with 500 μg/ml 125I-LDL. Total uptake of the 125I-LDL was reduced 68 ± 1% and 69 ± 2% in T0901317- and 22(R)-hydroxycholesterol-treated macrophages, respectively, compared with untreated control macrophages (Fig. 2). Treatment of macrophages with T0901317 did not affect the percentage of 125I-LDL that was degraded by the macrophages following uptake. Macrophages without and with T0901317 treatment degraded similar amounts of 125I-LDL in three experiments, 90 ± 1% and 88 ± 1%, respectively.

As expected, T0901317 inhibition of 125I-LDL uptake was paralleled by a decrease in macrophage cholesterol accumulation. Control macrophages showed a large increase in cholesterol content after LDL incubation (96 ± 5 to 463 ± 22 nmol/mg/cell protein), whereas T0901317-treated (5 μM) macrophages showed a much smaller increase in their cholesterol content after LDL incubation (47 ± 7 to 156 ± 6 nmol/mg/cell protein) (Fig. 3). Thus, T0901317 inhibited macrophage cholesterol accumulation by 70 ± 1% compared with controls (P < 0.05). Treatment of macrophages with 10 μM T0901317 rather than 5 μM did not result in greater inhibition of cholesterol accumulation (data not shown).

In an additional experiment, T0901317 was added to differentiating monocytes at different time points following initiation of the culture, resulting in 1, 3, 5, or 7 days of treatment (7 days indicating treatment from the beginning of culture). Then, as in the above experiment, after

---

Fig. 1. T0901317 treatment decreases macropinosomes in macrophages. Shown are phase photomicrographs of differentiated monocyte-derived macrophages following 7 day culture of monocytes in differentiation medium either without T0901317 (A), or in differentiation medium containing T0901317 (5 μM) (B). There are fewer macropinosome vacuoles in T0901317-treated macrophages compared with control macrophages. The bar is 50 μm and applies to both A and B.

Fig. 2. Liver X receptor (LXR) agonists decrease macrophage uptake of 125I-LDL. Monocytes were cultured for 7 days in differentiation medium without any LXR agonist or with T0901317 (5 μM) or 22(R)-hydroxycholesterol (5 μM). Then, the differentiated monocyte-derived macrophages were incubated for 1 day in serum-free differentiation medium containing the indicated LXR agonist treatment and 500 μg/ml 125I-LDL. Total uptake of the 125I-LDL was determined as the sum of cell-associated and degraded 125I-LDL as described in Materials and Methods. Error bars indicate ± SEM.
7 days of culture, the monocyte-derived macrophages were incubated for 1 day with 500 μg/ml 125I-LDL. Macrophage total uptake of 125I-LDL was progressively reduced as the time of T0901317 treatment was increased (Fig. 4). Maximal T0901317 inhibition (58 ± 1%) of 125I-LDL uptake occurred when the drug was administered from the beginning of the culture (i.e., 7 days of treatment). Only some inhibition (17 ± 2%) of 125I-LDL uptake occurred when T0901317 was added to macrophages 1 day before incubation of macrophages with LDL. Likewise, maximal T0901317 inhibition (72 ± 1%) of cholesterol accumulation occurred when the drug was administered from the beginning of the culture, whereas only some inhibition (28 ± 2%) of cholesterol accumulation occurred when T0901317 was added 1 day before incubation of macrophages with LDL.

**PPAR agonists do not decrease macrophage uptake of LDL.**

PPARα, β/δ, and γ are members of the nuclear receptor superfamily that regulate gene expression in response to the binding of fatty acids and their metabolites. PPARs have been shown to affect macrophage cholesterol metabolism, usually by modulation of LXR. For this reason, we tested whether differentiation of human monocytes into macrophages in the presence of PPAR agonists would also affect macrophage uptake of LDL similar to LXR agonists. Monocytes differentiated to macrophages over 7 days with either no agonist, the LXR agonist T0901317, the PPARα agonist clofibrate, the PPARβ/δ agonist L165,041, or the PPARγ agonist ciglitazone were incubated with 500 μg/ml 125I-LDL for 24 h. Only T0901317 inhibited 125I-LDL uptake by macrophages, whereas the PPAR agonists did not affect 125I-LDL uptake (Table 1).

**Decrease in macrophage fluid uptake induced by LXR agonist accounts for decrease in LDL uptake.**

In our earlier study, 125I-LDL uptake by M-CSF-differentiated macrophages was linear, showing no evidence of saturation with 125I-LDL concentrations up to as much as 500 μg/ml 125I-LDL is compared with controls.

**Table 1.** PPAR agonists do not affect macrophage uptake of 125I-LDL.

| Agonist          | Total 125I-LDL Uptake (μg/mg cell protein) | SEM     |
|------------------|-------------------------------------------|---------|
| No addition      | 160 ± 12                                   |         |
| T0901317         | 79 ± 18                                    |         |
| Clofibrate       | 142 ± 50                                   |         |
| L165,041         | 165 ± 21                                   |         |
| Ciglitazone      | 143 ± 11                                   |         |

Monocytes were cultured for 7 days in differentiation medium containing either no addition of agonist, liver X receptor agonist T0901317 (5 μM), PPARα agonist clofibrate (100 nM), PPARβ/δ agonist L165,041 (5 μM), or PPARγ agonist ciglitazone (5 μM). Then, the differentiated monocyte-derived macrophages were incubated for 24 h in serum-free medium containing the indicated agonist treatment and 500 μg/ml 125I-LDL. Total uptake of the 125I-LDL was determined as the sum of cell-associated and degraded 125I-LDL, as described in Materials and Methods. Results are expressed as means ± SEM. PPAR, peroxisome proliferator-activated receptor. *P = 0.003 when T0901317-treated macrophage uptake of 125I-LDL is compared with controls.
250 μg/ml (7). 125I-LDL uptake could not be inhibited by anti-LDL receptor antibody or even with an excess of unlabeled LDL. These findings showed that the mechanism of LDL uptake was fluid-phase pinocytosis rather than receptor-mediated endocytosis. In the present study, we compared the amount of fluid uptake by control and T0901317-treated macrophages to learn whether T0901317 inhibited macrophage fluid uptake, and if so, whether the inhibition of fluid uptake could account for the decrease in 125I-LDL uptake.

Macrophages take up BSA by fluid-phase pinocytosis, and so we used this probe to measure macrophage fluid uptake, as was done previously (7, 27). One set of T0901317-treated and control macrophages was incubated for 24 h with 250 μg/ml 125I-BSA, and another set of macrophages for each experimental condition was incubated with 250 μg/ml 125I-LDL. As we showed previously (7), the entire amount of 125I-LDL uptake could be accounted for by fluid-phase pinocytosis, inasmuch as the total macrophage uptake of 125I-LDL and 125I-BSA incubated at the same concentrations was similar (Table 2). The amount of 125I-BSA uptake was reduced by about 60% in T0901317-treated macrophages compared with controls, and this inhibition was similar to T0901317 inhibition of 125I-LDL uptake (Table 2). Thus, LXR agonist-mediated decrease in macrophage fluid-phase pinocytosis accounted for the decrease in 125I-LDL uptake.

LXR agonist affects predominantly fluid-phase pinocytosis rather than receptor-mediated endocytosis

To investigate whether the effect of T0901317 is specific for fluid-phase pinocytosis, we examined whether T0901317 has an inhibitory effect on receptor-mediated endocytosis of 125I-acetylated LDL, known to be taken up by macrophage scavenger receptors (32–34). First, we examined the concentration dependence of 125I-acetylated LDL uptake, known to be taken up by fluid-phase pinocytosis, inasmuch as the total macrophage uptake of 125I-acetylated LDL and 125I-BSA incubated at the same concentrations was similar (Table 2). The amount of 125I-BSA uptake was reduced by about 60% in T0901317-treated macrophages compared with controls, and this inhibition was similar to T0901317 inhibition of 125I-LDL uptake (Table 2). Thus, LXR agonist-mediated decrease in macrophage fluid-phase pinocytosis accounted for the decrease in 125I-LDL uptake.

| Condition          | Total 125I-LDL Uptake μg/mg cell protein | Inhibition % |
|--------------------|------------------------------------------|--------------|
| 125I-LDL + T0901317 | 7.5 ± 0.2                               |              |
| 125I-BSA           | 67 ± 6                                   | 60           |

Monocytes were cultured for 7 days in differentiation medium without or with 5 μM T0901317. Then, T0901317-treated and control macrophages were incubated for 1 day with 25 μg/ml 125I-acetylated LDL or 250 μg/ml 125I-BSA as a measure of fluid-phase pinocytosis. Total uptake was determined as the sum of the cell-associated and degraded 125I-LDL or 125I-BSA, as described in Materials and Methods. Results are expressed as means ± SEM.

TABLE 2. Effect of T0901317 on fluid-phase pinocytosis

| 125I-BSA | 125I-LDL | 125I-acetylated LDL | 125I-acetylated LDL + |
|----------|----------|---------------------|----------------------|
| 70 ± 17  | 27 ± 4   | 13.9 ± 1.1          | 84.6 ± 6.4           |

To examine receptor-mediated uptake of 125I-acetylated LDL, we used methyl-β-cyclodextrin (5 mM) for 1 h. Methyl-β-cyclodextrin inhibits phorbol ester-induced macropinocytosis in the human epithelial carcinoma cell line A421 (29). We observed that T0901317 treatment significantly decreased basal cholesterol levels in the macrophages by about 50% (Fig. 3). Thus, we considered the possibility that T0901317-induced depletion of macrophage cholesterol was the mechanism by which T0901317 decreased pinocytosis. To test this idea, macrophage cholesterol content was decreased by treating macrophages with methyl-β-cyclodextrin (5 mM) for 1 h. Then, macrophages were incubated with unlabeled BSA (250 μg/ml) for 5 h before determination of macrophage cholesterol content. After the 1 h incubation with methyl-β-cyclodextrin, macrophage cholesterol content decreased 44% compared with untreated control macrophages, and decreased further to 25% of control macrophage values after a 5 h incubation with BSA. The cholesterol content in all experimental conditions for these unloaded macrophages was ≈95% unesterified. In a parallel experiment, methyl-β-cyclodextrin-pretreated and -untreated control macrophages were incubated with 125I-BSA (250 μg/ml) for 5 h to measure fluid uptake. It was determined that macrophage cholesterol depletion...
TABLE 4. Effect of macrophage cholesterol content on fluid-phase pinocytosis

| Parameter Measured | Treatment | Methyl-β-cyclodextrin | + Methyl-β-cyclodextrin |
|--------------------|-----------|------------------------|-------------------------|
| Total cell cholesterol content | nmol/mg cell protein | Before treatment | 117 ± 2 | 117 ± 2 |
|                      |           | After 1 h treatment   | 121 ± 6 | 53 ± 1 |
|                      |           | After 1 h treatment followed by additional 5 h treatment | 108 ± 2 | 29 ± 2 |
| Total 125I-BSA uptake | µg/mg cell protein | Before treatment | 20 ± 1 | 23 ± 2 |
|                      |           | After 1 h treatment followed by additional 5 h treatment | 20 ± 1 | 23 ± 2 |

Monocytes were cultured for 7 days in differentiation medium. Then, the macrophages were pretreated for 1 h with and without methyl-β-cyclodextrin (5 mM) added to serum-free differentiation medium. This was followed by 5 h incubation with and without methyl-β-cyclodextrin and either unlabeled BSA (250 µg/ml) or 125I-BSA (250 µg/ml) for determination of cholesterol content and assessment of fluid-phase pinocytosis, respectively, as described in Materials and Methods. Results are expressed as means ± SEM.

DISCUSSION

It is believed that LXR upregulation of cholesterol efflux genes underlies the anti-atherosclerotic effects of LXR activation observed in mouse models of atherosclerosis (as reviewed in Refs. 35, 36). Promoting cholesterol efflux from macrophage foam cells in atherosclerotic plaques could initiate removal of cholesterol from atherosclerotic plaques. However, macrophage cholesterol accumulation depends also on the uptake of cholesterol as well as the compensatory efflux of excess cholesterol. Our findings show for the first time that LXR agonists can regulate cholesterol accumulation not only by regulating cholesterol efflux but also by regulating macrophage uptake of LDL.

The culture model used for the research reported here is characterized by human monocyte-derived macrophages that constitutively take up large amounts of native LDL by fluid-phase pinocytosis (7). The widely accepted hypothesis for foam cell formation involves receptor-mediated endocytosis of modified or aggregated LDL (3, 4). Pinocytosis of fluid-phase rather than bound LDL is a novel mechanism of macrophage cholesterol accumulation (5–7). We have shown here that both synthetic and natural LXR agonists, T0901317 and 22(R)-hydroxycholesterol, downregulated macrophage LDL uptake by inhibiting fluid-phase pinocytosis of native LDL. T0901317 did not affect receptor-mediated endocytosis of acetylated LDL, showing that LXR specifically inhibits lipoprotein uptake mediated by fluid-phase pinocytosis.

PPARα, β/δ, and γ also regulate genes involved in the control of lipid metabolism and inflammation, and it has been suggested that there is “cross talk” between PPARs and LXR pathways during regulation of the cholesterol efflux pathway in macrophages (35). It has been reported that PPAR agonists can increase expression of LXRα but not LXRβ in mouse macrophages and human monocyte-derived macrophages (17, 37). In the research reported here, we found that PPAR agonists targeting each of the three classes of PPARs failed to modulate LDL uptake. Only macrophages differentiated in the presence of LXR agonists (but not PPAR agonists) showed significant reduction of LDL uptake compared with control macrophages. It remains to be determined why PPAR agonists that regulate LXR expression in other macrophage systems showed no effect on the LXR-mediated downregulation of pinocytosis in these human macrophages.

LXR agonist-induced modulation of macrophage pinocytosis showed a progressively increasing inhibition of pinocytosis during the 7 day treatment with T0901317. This finding that maximal inhibition required 7 days of treatment with T0901317 suggests the possibility that genes indirectly regulated by LXR may have mediated the inhibition of pinocytosis. However, we have observed that some genes in macrophages previously shown to be directly regulated by LXR nevertheless require more than 4 days of T0901317 treatment before maximal gene expression occurs (Y. Li, C. Buono, S. W. Waldo, and H. S. Kruth, unpublished observation).

Pinocytosis in our macrophage culture system was mediated in part by macropinocytosis, which, as we have shown previously, occurs in these human M-CSF-differentiated monocyte-derived macrophages. Macropinocytosis is a mechanism of fluid-phase pinocytosis described under certain conditions in other cell types, such as fibroblasts, epithelial cells, and dendritic cells. In dendritic cells, macropinocytosis functions in antigen processing (8, 38). In the human epithelial carcinoma cell line A431, macropinocytosis induced by activation of PKC with phorbol ester 12-O-tetradecanoylphorbol 13-acetate is regulated by the cholesterol content of the plasma membrane (29). When A431 epithelial cells were pretreated with methyl-β-cyclodextrin to extract cholesterol, the phorbol ester was unable to induce increased fluid-phase pinocytosis. Because LXR agonist treatment decreased basal cholesterol levels in the macrophages (probably due to stimulation of cholesterol efflux as discussed above), we considered that the mechanism of reduced fluid-phase pinocytosis by LXR-treated macrophages might be due to diminished plasma membrane cholesterol content mediated by LXR-stimulated cholesterol efflux. However, this was not the case; we found no reduction of constitutive fluid-phase pinocytosis in macrophages depleted of cholesterol by treatment with methyl-β-cyclodextrin. Thus, an LXR agonist-induced decrease in macropinocytosis content is not the mechanism by which LXRs regulate pinocytosis in M-CSF-differentiated human macrophages.

On the other hand, increased macrophage cholesterol content due to macropinocytosis of LDL would be expected to generate endogenous oxysterol LXR agonists (39). This should tend to downregulate macropinocytosis
of LDL assuming that oxysterols are generated. However, we previously published that macrophagic uptake of LDL does not downregulate macropinocytosis over a 2 day period, despite substantial macrophage cholesterol accumulation (7). That finding is consistent with what we have shown here, in that LXR activation must occur for longer than 2 days before macropinocytosis is substantially downregulated.

In conclusion, we have shown that activation of LXR transcription factors may be atheroprotective by a novel mechanism that decreases macrophage receptor-independent, fluid-phase pinocytosis of atherogenic lipoproteins such as LDL. In addition, pinocytosis leads to fluid-phase uptake and degradation of the anti-atherogenic HDL (7) and unpublished data. Thus, LXR-mediated decrease in macrophage pinocytosis of HDL may also beatheroprotective by increasing plaque HDL that is available to mediate reverse cholesterol transport. It is well known that LXRs, as transcription factors, regulate expression of several genes in macrophages, and it is very likely that some of those are directly or indirectly involved in the inhibitor effect of LXRs on pinocytosis. It will be of interest in future research to learn which LXR-regulated genes affect pinocytosis.

The authors thank the Department of Transfusion Medicine, Clinical Center, National Institutes of Health (NIH), for providing elutriated monocytes and Rani Rao for technical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Heart, Lung, and Blood Institute. The Howard Hughes Medical Institute-NIH Medical Research Scholar Program provided support for S.W.W.

REFERENCES

1. Bobryshev, Y. V. 2006. Monocyte recruitment and foam cell formation in atherosclerosis. Microcirc. 37: 208–222.
2. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685–1695.
3. Kunjathoor, V. V., M. Febbraio, E. A. Podrez, K. J. Moore, L. Andersson, S. Koehn, J. S. Rhee, R. Silverstein, H. F. Hoff, and M. W. Freeman. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277: 49982–49988.
4. Steinberg, D. 1997. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherosclerosis. Circulation. 95: 1062–1071.
5. Kruth, H. S., W. Huang, I. Ishii, and W. Y. Zhang. 2002. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 277: 34573–34580.
6. Kruth, H. S., N. L. Jones, W. Huang, B. Zhao, I. Ishii, J. Chang, C. A. Combs, D. Malide, and W. Y. Zhang. 2005. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280: 2352–2356.
7. Zhao, B., Y. Li, C. Buono, S. W. Waldo, N. L. Jones, M. Mori, and H. S. Kruth. 2006. Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF). J. Biol. Chem. 281: 15757–15762.
8. Anyere, M., M. Mettlen, P. Van Der Smissten, A. Platek, P. Bayrastre, A. Veithen, and P. J. Courtouy. 2002. Origin, originality, functions, subdivisions and molecular signalling of macropinocytosis. Int. J. Mol. Microbiol. 291: 487–494.
9. Swanson, J. A., and C. Watts. 1995. Macropinocytosis. Trends Cell Biol. 5: 424–428.
10. Ma, H. T., W. W. Lin, B. Zhao, W. T. Wu, W. Huang, Y. Li, N. L. Jones, and H. S. Kruth. 2006. Protein kinase C beta and delta isoforms mediate cholesterol accumulation in PMA-activated macrophages. Biochim. Biophys. Res. Commun. 349: 214–220.
11. Zelker, N., and P. Kontonou. 2006. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607–614.
12. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7690–7695.
13. Terasawa, N., A. Hiroshima, T. Koyama, N. Ubuoka, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-9090137, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 5–11.
14. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135–142.
15. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Waleczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11906–11910.
16. Mak, P. A., B. A. Laffitte, C. Desrumaux, S. B. Joseph, L. K. Curtiss, D. J. Mangelsdorf, P. Kontonou, and P. A. Edwards. 2002. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277: 31960–31968.
17. Chawla, A. W., A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7: 161–171.
18. Rigamonti, E., L. Helin, S. Lestavel, A. L. Mutka, M. Lepore, C. Fontaine, M. A. Bouthil, S. Buller, J. Fruchat, E. Ikonen, et al. 2005. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 97: 682–689.
19. Naik, S. U., X. Wang, J. S. Da Silva, M. Jave, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113: 90–97.
20. Cignarella, A., T. Engel, A. von Eckardstein, M. Kratz, S. Lorowski, A. Lueken, G. Assmann, and P. Cullen. 2005. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis. 179: 255–266.
21. Li, A. C., C. J. Binder, A. Gutierrez, K. K. Brown, C. R. Plotkin, J. W. Pattinson, A. F. Valledor, R. A. Davis, T. W. Willson, J. L. Witzum, et al. 2004. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114: 1564–1576.
22. Sparrow, C. P., J. Baffic, M. H. Lam, E. G. Lund, A. D. Adams, X. Fu, N. Hayes, A. B. Jones, M. A. Macaulay, J. Onedeka, et al. 2002. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277: 10021–10027.
23. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABC1 gene expression and ApoAI-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274: 794–802.
24. Venkateswaran, A., B. A. Laffitte, S. B. Joseph, P. A. Mak, D. C. Wilpitz, P. A. Edwards, and P. Kontonou. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97: 12097–12102.
25. Laffitte, B. A., J. J. Repa, S. B. Joseph, D. C. Wilpitz, H. R. Kast, D. J. Mangelsdorf, and P. Kontonou. 2001. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA. 98: 507–512.
26. Hashimoto, S., M. Yamada, K. Motovoysh, and K. S. Akagawa. 1997. Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood. 90: 315–321.
27. Goldstein, J. L., and M. S. Brown. 1974. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 240: 5153–5162.
28. Lowry, O. H., N. J. Rosebrough, and A. L. Farr. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265–275.
29. Grimmer, S., B. van Deurs, and K. Sandvig. 2002. Membrane ruffling and macropinocytosis in A431 cells require cholesterol. J. Cell Sci. 115: 2953–2962.
30. Kruth, H. S., S. I. Skarlatos, K. Lilly, J. Chang, and I. Ifrim. 1995. Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J. Cell Biol. 129: 133–145.
31. Akiyama, T. E., S. Sakai, G. Lambert, C. J. Nicol, K. Matsusue, S. Pimprale, Y. H. Lee, M. Ricote, C. K. Glass, H. B. Brewer, Jr., et al. 2002. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22: 2607–2619.
32. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98: 241–250.
33. Mazzone, T., C. Lopez, and L. Bergstrasser. 1987. Modification of very low density lipoproteins leads to macrophage scavenger receptor uptake and cholesteryl ester deposition. Arteriosclerosis. 7: 191–196.
34. Leake, D. S., G. May, A. A. Soyombo, and M. H. Nasr-Esfahani. 1989. The effect of macrophage stimulation on the uptake of acetylated low-density lipoproteins. Biochim. Biophys. Acta. 1005: 196–200.
35. Li, A. C., and C. K. Glass. 2004. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45: 2161–2173.
36. Castrillo, A., and P. Tontonoz. 2004. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20: 455–480.
37. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53–58.
38. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389–400.
39. Fu, X., J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow, and E. G. Lund. 2001. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378–38387.